These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 20689132)
101. Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer. Bose CK Future Oncol; 2013 Sep; 9(9):1257-61. PubMed ID: 23980671 [No Abstract] [Full Text] [Related]
102. Proteomic analysis at the bedside: early detection of cancer. Petricoin EF; Liotta LA Trends Biotechnol; 2002 Dec; 20(12 Suppl):S30-4. PubMed ID: 12570157 [TBL] [Abstract][Full Text] [Related]
103. Water molecule movement may be the key to monitoring success of ovarian cancer treatment. Mayor S BMJ; 2012 Feb; 344():e1229. PubMed ID: 22349584 [No Abstract] [Full Text] [Related]
104. Biomarker discovery and validation: the tide is turning. Nice E Expert Rev Proteomics; 2013 Dec; 10(6):505-7. PubMed ID: 24206223 [No Abstract] [Full Text] [Related]
105. Proteomics and ovarian cancer: integrating proteomics information into clinical care. Hays JL; Kim G; Giuroiu I; Kohn EC J Proteomics; 2010 Sep; 73(10):1864-72. PubMed ID: 20561909 [TBL] [Abstract][Full Text] [Related]
106. New guidelines for early detection of ovarian cancer. Lancet; 2011 May; 377(9777):1544. PubMed ID: 21550466 [No Abstract] [Full Text] [Related]
107. Proteomics for the Identification of Biomarkers in Testicular Cancer-Review. Milardi D; Grande G; Vincenzoni F; Pierconti F; Pontecorvi A Front Endocrinol (Lausanne); 2019; 10():462. PubMed ID: 31354629 [TBL] [Abstract][Full Text] [Related]
108. Energy metabolism and changes in cellular composition in ovarian cancer. Malek A Methods Mol Biol; 2013; 1049():233-8. PubMed ID: 23913220 [TBL] [Abstract][Full Text] [Related]
109. Ovarian cancer biomarkers: a focus on genomic and proteomic findings. Tinelli A; Vergara D; Martignago R; Leo G; Malvasi A; Tinelli R; Marsigliante S; Maffia M; Lorusso V Curr Genomics; 2007 Aug; 8(5):335-42. PubMed ID: 19384429 [TBL] [Abstract][Full Text] [Related]
110. Is early detection of cancer with circulating biomarkers feasible? Konforte D; Diamandis EP Clin Chem; 2013 Jan; 59(1):35-7. PubMed ID: 22522223 [No Abstract] [Full Text] [Related]
111. Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. Bast RC Cancer Biomark; 2010-2011; 8(4-5):161-6. PubMed ID: 22045350 [No Abstract] [Full Text] [Related]
112. Stroke Proteomics: From Discovery to Diagnostic and Therapeutic Applications. Hochrainer K; Yang W Circ Res; 2022 Apr; 130(8):1145-1166. PubMed ID: 35420912 [TBL] [Abstract][Full Text] [Related]
113. Ovarian cancer biomarker discovery based on genomic approaches. Lee JY; Kim HS; Suh DH; Kim MK; Chung HH; Song YS J Cancer Prev; 2013 Dec; 18(4):298-312. PubMed ID: 25337559 [TBL] [Abstract][Full Text] [Related]
114. Biomarkers for diagnosis: looking for change. Fisher M Biomark Med; 2015; 9(12):1275-7. PubMed ID: 26612585 [No Abstract] [Full Text] [Related]
115. Focus on cancer proteomics: from discovery towards validation. Gallagher WM Proteomics Clin Appl; 2010 Jul; 4(6-7):577-8. PubMed ID: 21137075 [No Abstract] [Full Text] [Related]